Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dopamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 5/20 | 0.73 |
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.73 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.73 |
| ▸ | DRD2 | P14416 | 2/20 | 0.73 |
| ▸ | DRD1 | P21728 | 2/20 | 0.73 |
| ▸ | DRD4 | P21917 | 2/20 | 0.73 |
| ▸ | DRD5 | P21918 | 2/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.73 |
| ▸ | DRD3 | P35462 | 2/20 | 0.73 |
| ▸ | RECQL | P46063 | 2/20 | 0.73 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | TP53 | P04637 | 2/20 | 0.73 |
| ▸ | THPO | P40225 | 2/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dopamine SCHEMBL29435413 | 1.00 | ALOX15 (0.73) | ALOX15MAPTKDM4EMAPK1ADRA2A | |
| Dopamine SCHEMBL29599861 | 0.98 | MAPT (0.74) | ALOX15MAPTKDM4EMAPK1ADRA2A | |
| Dopamine SCHEMBL29456593 | 0.88 | ALOX15 (0.73) | ALOX15MAPTKDM4EMAPK1ADRA2A | |
| Dopamine SCHEMBL50897 | 0.88 | ALOX15 (0.73) | ALOX15MAPTKDM4EMAPK1ADRA2A | |
| Dopamine SCHEMBL29362033 | 0.85 | KDM4E (1.00) | ALOX15MAPTKDM4EMAPK1ADRA2A | |
| Dopamine SCHEMBL8505 | 0.85 | KDM4E (1.00) | ALOX15MAPTKDM4EMAPK1ADRA2A | |
| Dopamine SCHEMBL9166387 | 0.85 | KDM4E (1.00) | ALOX15MAPTKDM4EMAPK1ADRA2A | |
| Dopamine SCHEMBL496657 | 0.85 | KDM4E (1.00) | ALOX15MAPTKDM4EMAPK1ADRA2A | |
| Dopamine SCHEMBL29375089 | 0.85 | KDM4E (1.00) | ALOX15MAPTKDM4EMAPK1ADRA2A | |
| Dopamine SCHEMBL18159501 | 0.85 | KDM4E (1.00) | ALOX15MAPTKDM4EMAPK1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14732 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768271-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2026-02-18 | — | — | EP | claimed |
| US-20250312308-A1 | METHODS OF TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | SUMITOMO PHARMA AMERICA, INC. (US) | 2025-10-09 | — | — | US | claimed |
| US-20250243201-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-07-31 | — | — | US | claimed |
| US-20250228778-A1 | PLATFORM DRUG DELIVERY SYSTEM UTILIZING CRYSTAL ENGINEERING AND THEANINE DISSOLUTION | THEAPRIN PHARMACEUTICALS INC (US) | 2025-07-17 | — | — | US | claimed |
| US-20250197397-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-06-19 | — | — | US | claimed |
| WO-2025122610-A1 | THERAPEUTIC COMBINATIONS AND METHODS FOR 5-HT3 RECEPTOR MODULATORS IN TREATING VARIOUS DISORDERS | SEROTONIX LLC (US) | 2025-06-12 | — | — | WO | claimed |
| US-12269825-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-04-08 | — | — | US | claimed |
| CN-119700765-A | Di-Caulophyllum dopamine D2 receptor agonist, application thereof and pharmaceutical composition | 中国科学院大连化学物理研究所 | 2025-03-28 | — | — | CN | claimed |
| CN-119538993-A | Pilot safety risk analysis method and system based on nerve computation | 南京航空航天大学 | 2025-02-28 | — | — | CN | claimed |
| WO-2025031459-A1 | AZA-ERGOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 上海医药集团股份有限公司 | 2025-02-13 | — | — | WO | claimed |
| EP-0514490-B1 | ALLELIC ASSOCIATION OF THE HUMAN DOPAMINE (D2) RECEPTOR GENE IN COMPULSIVE DISORDERS SUCH AS ALCOHOLISM | UNIV TEXAS (US) | 1996-06-26 | — | — | EP | claimed |
| US-5500343-A | SUSCEPTIBILITY TO ALCOHOLISM, COCAINE DEPENDENCE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1996-03-19 | — | — | US | claimed |
| WO-1996000062-A1 | DOPAMINE D1 AGONISTS FOR THE TREATMENT OF DEMENTIA | INTERNEURON PHARMACEUTICALS, INC. (US) | 1996-01-04 | — | — | WO | claimed |
| US-5480631-A | Radioiodinated benzamines and method of their use as radioimaging | VANDERBILT UNIVERSITY (US) | 1996-01-02 | — | — | US | claimed |
| WO-1995028157-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1995-10-26 | — | — | WO | claimed |
| EP-0667769-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1995-08-23 | — | — | EP | claimed |
| WO-1994010989-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1994-05-26 | — | — | WO | claimed |
| EP-0538395-A1 | NUCLEIC ACID SEQUENCES ENCODING A HUMAN DOPAMINE D 1? RECEPTOR | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1993-04-28 | — | — | EP | claimed |
| WO-1992000986-A1 | NUCLEIC ACID SEQUENCES ENCODING A HUMAN DOPAMINE D1 RECEPTOR | NEUROGENETIC CORPORATION (US) | 1992-01-23 | — | — | WO | claimed |
| WO-1991005040-A1 | CLONED GENES FOR HUMAN DOPAMINE D2 RECEPTORS AND CELL LINES EXPRESSING SAME | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, UNITED STATES DEPARTMENT OF COMMERCE (US) | 1991-04-18 | — | — | WO | claimed |